Ratings and Reviews
154 Ratings 16 Comments
|CP concern for questions/worries||4.9|
|CP efforts to include in decisions||4.9|
|CP explanations of prob/condition||4.9|
|CP spoke using clear language||4.9|
|Friendliness/courtesy of CP||4.9|
|Likelihood of recommending CP||4.9|
|Patients' confidence in CP||4.9|
|Time CP spent with patient||4.8|
|Wait time at clinic||3.9|
The overall Patient Rating score is the average of responses to the nine questions listed below. The questions are from the Press Ganey Patient Experience Survey. Responses are measured on a 1 to 5 scale, where 1 represents "very poor" and 5 represents "very good.
- BSE, Duke University, 1976
- MD, University of North Carolina at Chapel Hill School of Medicine, 1980
- Internal Medicine, North Carolina Baptist Hospital, 1983
- North Carolina Baptist Hospital, 1986
- American Board of Internal Medicine, Internal Medicine
- American Board of Internal Medicine, Medical Oncology
- American College of Physicians
- Association of Medical School Professors of Psychology
- Cancer & Acute Leukemia Group
- American Society of Clinical Oncology
- American Society of Hematology
- Section Chief, Hematology and Oncology
- Director-At-Large, Comprehensive Cancer Center
- Professor, Hematology and Oncology
Wake Forest Baptist accepts most major health insurance plans for hospital, physician and clinic services and participates in Medicare and Medicaid government programs. For more information, visit Billing and Insurance.
This chart is a list of the most common health insurance plans we accept. This list is subject to change. Please check your individual plan to confirm their participation and the coverage allowed.
Due to the different physician groups and hospitals within the Wake Forest Baptist system, physician services and hospital services are billed separately. Please remember that health insurance coverage varies, so some services may not be covered.
If you don’t see your plan or you have questions, please call our Customer Service Center at 877-938-7497. We will do our best to work with you and your plan.
WFUHS - Wake Forest University Health Sciences (physician services)
NCBH - North Carolina Baptist Hospital
Davie - Davie Medical Center
LMC - Lexington Medical Center
CHC - Cornerstone Healthcare
Wilkes - Wilkes Regional Medical Center
N/A - Not applicable to services provided at facility and/pr CHC
NC - Not contracted, very low to no volume for facility and/or CHC
|WAKE FOREST BAPTIST HEALTH|
|MANAGED CARE CONTRACTS - December 2017|
|AETNA (PPO & HMO)||X||X||X||X||X||X|
|BCBSNC (PPO & HMO)||X||X||X||X||X||X|
|CAROLINA BEHAVIORAL HEALTH||X||X||N/A||N/A||X||N/A|
|CIGNA BEHAVIORAL HEALTH||X||N/A||N/A||N/A||N/A|
|CIGNA HEALTHSPRING MEDICARE ADVANTAGE||X||X||X||X||X||N/A|
|CIGNA LIFESOURCE (TRANSPLANTS)||X||X||N/A||N/A||N/A||N/A|
|CRESCENT PPO (ASHEVILLE)||X||X||NC||NC||NC||NC|
|FIRST HEALTH (COVENTRY)||X||X||X||X||X||X|
|FIRSTCAROLINACARE (PINEHURST, NC)||NC||X||NC||NC||NC||NC|
|GATEWAY HEALTH ALLIANCE (VIRGINIA)||X||X||NC||NC||NC||NC|
|GOLDEN RULE INS (UNITED)||X||X||X||X||X||X|
|HEALTHGRAM (formerly PRIMARY PHYSICIAN CARE)||X||X||NC||X||NC||NC|
|HUMANA MEDICARE ADVANTAGE||X||X||X||X||X||X|
|LIBERTY ADVANTAGE (MEDICARE ADVANTAGE)||X||X||N/A||N/A||N/A||N/A|
|MAGELLAN (BEHAVIORAL HEALTH)||X||X||N/A||N/A||X||N/A|
|OPTUMHEALTH (TRANSPLANTS - APPLICABLE TO NCBH/WFUHS ONLY)||X||X||N/A||N/A||N/A||N/A|
|PREFERRED CARE OF VA INC||X||X||NC||NC||NC||NC|
|SOUTHERN HEALTH SVCS (COVENTRY-PPO ONLY)||X||X||X||NC||X||NC|
|TWIN COUNTY (VIRGINIA)||X||X||NC||NC||NC||NC|
|UNITED BEHAVIORAL HEALTH||X||X||N/A||N/A||X||N/A|
|UNITED BEHAVIORAL HEALTH INTENSIVE OUTPATIENT PROGRAM (WFUHS ONLY)||X||N/A||N/A||N/A||N/A||N/A|
|UNITED HEALTHCARE MEDICARE||X||X||X||X||X||X|
|LEXINGTON ONLY - Contracts specific to support Lexington employer groups, low volume|
|NATIONAL PROVIDER NETWORK/MEDICAL RESOURCES|
|CHC ONLY - Contracts specific to support CHC|
|AETNA BEHAVIORAL HEALTH|
CIGNA BEHAVIORAL HEALTH (limited providers)
|THN - TRIAD HEALTH NETWORK MA Plans only (Humana Medicare and Healthteam Advantage)|
|N/A = not applicable to services provided at facility and/or CHC|
|NC = Not Contracted, very low to no volume for facility and/or CHC|
|WFUHS - Wake Forest University Health Sciences (professional services)|
|NCBH - North Carolina Baptist Hospital|
|DAVIE - Davie Medical Center|
|LMC - Lexington Medical Center|
|CHC - Cornerstone Healthcare|
|Wilkes - Wilkes Regional Medical Center|
- Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission.. Vasu S, Kohlschmidt J, Mrózek K, Eisfeld AK, Nicolet D, Sterling LJ, Becker H, Metzeler KH, Papaioannou D, Powell BL, Kolitz JE, Moore JO, Baer MR, Roboz GJ, Stone RM, Byrd JC, Carroll AJ, Bloomfield CD. Blood Adv. 2018 Jul; 2(13):1645-1650.
- NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome.. Eisfeld AK, Kohlschmidt J, Mrózek K, Mims A, Walker CJ, Blachly JS, Nicolet D, Orwick S, Maharry SE, Carroll AJ, Powell BL, Kolitz JE, Wang ES, Stone RM, de la Chapelle A, Byrd JC, Bloomfield CD. Leukemia. 2018 Dec; 32(12):2536-2545.
- Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies.. Eisfeld AK, Kohlschmidt J, Mrózek K, Blachly JS, Walker CJ, Nicolet D, Orwick S, Maharry SE, Carroll AJ, Stone RM, de la Chapelle A, Wang ES, Kolitz JE, Powell BL, Byrd JC, Bloomfield CD. Leukemia. 2018 Jun; 32(6):1338-1348.
- A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia.. Pardee TS, Anderson RG, Pladna KM, Isom S, Ghiraldeli LP, Miller LD, Chou JW, Jin G, Zhang W, Ellis LR, Berenzon D, Howard DS, Hurd DD, Manuel M, Dralle S, Lyerly S, Powell BL. Clin. Cancer Res. 2018 May; 24(9):2060-2073.
- Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia.. Ngankeu A, Ranganathan P, Havelange V, Nicolet D, Volinia S, Powell BL, Kolitz JE, Uy GL, Stone RM, Kornblau SM, Andreeff M, Croce CM, Bloomfield CD, Garzon R. Oncotarget. 2018 Jan; 9(4):4354-4365.
- A Phase IB/II Multi-Arm Study with Venetoclax in Combination with Cobimetinib and Venetoclax in Combination with Cobimetinib and Indasanutlin in Patients Aged > 60 years with Relapsed or Refractory Acute Myeloid Leukemia who are not Eligible for Cytotoxic Therapy
- Feasibility of CPI-613 for Acute Myeloid Lekumia
- Treatment with an experimental drug in patients with newly diagnosed Acute Lymphoblastic Leukemia.